Ultragenyx buys gene therapy partner after new study results

Ultragenyx buys gene therapy partner after new study results

Source: 
BioPharma Dive
snippet: 

Ultragenyx Pharmaceuticals has acquired privately held GeneTx BioTherapeutics for $75 million, convinced an experimental therapy the two companies are developing has promise for treating a rare neurogenetic condition known as Angelman syndrome.